Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

The Effect of Atorvastatin (and Subsequent Metformin) on Adipose Tissue Acylation-Stimulatory-Protein Concentration and Inflammatory Biomarkers in Overweight/Obese Women With Polycystic Ovary Syndrome.

Sathyapalan T, Hobkirk JP, Javed Z, Carroll S, Coady AM, Pemberton P, Smith A, Cianflone K, Atkin SL.

Front Endocrinol (Lausanne). 2019 Jun 25;10:394. doi: 10.3389/fendo.2019.00394. eCollection 2019.

2.

The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome.

Dawson AJ, Sathyapalan T, Vince R, Coady AM, Ajjan RA, Kilpatrick ES, Atkin SL.

Front Endocrinol (Lausanne). 2019 Apr 2;10:189. doi: 10.3389/fendo.2019.00189. eCollection 2019.

3.

The effects of treatment with liraglutide on quality of life and depression in young obese women with PCOS and controls.

Kahal H, Kilpatrick E, Rigby A, Coady A, Atkin S.

Gynecol Endocrinol. 2019 Feb;35(2):142-145. doi: 10.1080/09513590.2018.1505848. Epub 2019 Jan 1.

PMID:
30599799
4.

The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome.

Sathyapalan T, Coady AM, Kilpatrick ES, Atkin SL.

Endocr Connect. 2017 Nov;6(8):811-816. doi: 10.1530/EC-17-0217. Epub 2017 Oct 10.

5.

Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss.

Dawson AJ, Kilpatrick ES, Coady AM, Elshewehy AMM, Dakroury Y, Ahmed L, Atkin SL, Sathyapalan T.

BMC Endocr Disord. 2017 Jul 14;17(1):41. doi: 10.1186/s12902-017-0194-2.

6.

Androsterone glucuronide to dehydroepiandrosterone sulphate ratio is discriminatory for obese Caucasian women with polycystic ovary syndrome.

Cho LW, Sathyapalan T, Kilpatrick ES, Keevil BG, Miller AG, Coady AM, Ahmed L, Atkin SL.

BMC Endocr Disord. 2017 May 19;17(1):26. doi: 10.1186/s12902-017-0177-3.

7.

Endocannabinoid receptor blockade increases vascular endothelial growth factor and inflammatory markers in obese women with polycystic ovary syndrome.

Sathyapalan T, Javed Z, Kilpatrick ES, Coady AM, Atkin SL.

Clin Endocrinol (Oxf). 2017 Mar;86(3):384-387. doi: 10.1111/cen.13239. Epub 2016 Oct 7.

PMID:
27651218
8.

Endocannabinoid receptor blockade increases hepatocyte growth factor and reduces insulin levels in obese women with polycystic ovary syndrome.

Sathyapalan T, Dakroury Y, Ahmed L, Elshewehy AM, Kilpatrick ES, Coady AM, Atkin SL.

Clin Endocrinol (Oxf). 2016 Oct;85(4):671-3. doi: 10.1111/cen.13120. Epub 2016 Jun 23. No abstract available.

PMID:
27256522
9.

Differential Requirements for eIF4E Dose in Normal Development and Cancer.

Truitt ML, Conn CS, Shi Z, Pang X, Tokuyasu T, Coady AM, Seo Y, Barna M, Ruggero D.

Cell. 2015 Jul 2;162(1):59-71. doi: 10.1016/j.cell.2015.05.049. Epub 2015 Jun 18.

10.

The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls.

Kahal H, Aburima A, Ungvari T, Rigby AS, Coady AM, Vince RV, Ajjan RA, Kilpatrick ES, Naseem KM, Atkin SL.

BMC Endocr Disord. 2015 Apr 2;15:14. doi: 10.1186/s12902-015-0005-6.

11.

Postprandial effects of long-term niacin/laropiprant use on glucose and lipid metabolism and on cardiovascular risk in patients with polycystic ovary syndrome.

Aye MM, Kilpatrick ES, Afolabi P, Wootton SA, Rigby AS, Coady AM, Sandeman DD, Atkin SL.

Diabetes Obes Metab. 2014 Jun;16(6):545-52. doi: 10.1111/dom.12255. Epub 2014 Feb 9.

PMID:
24401089
12.

Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease.

Kahal H, Abouda G, Rigby AS, Coady AM, Kilpatrick ES, Atkin SL.

Clin Endocrinol (Oxf). 2014 Oct;81(4):523-8. doi: 10.1111/cen.12369. Epub 2013 Dec 12.

PMID:
24256515
13.

A comparison of cardiovascular risk indices in patients with polycystic ovary syndrome with and without coexisting nonalcoholic fatty liver disease.

Dawson AJ, Sathyapalan T, Smithson JA, Vince RV, Coady AM, Ajjan R, Kilpatrick ES, Atkin SL.

Clin Endocrinol (Oxf). 2014 Jun;80(6):843-9. doi: 10.1111/cen.12258. Epub 2013 Aug 26.

PMID:
23746214
14.

Twin pregnancy with a complete hydatidiform mole and co-existent healthy fetus: unusual case of complete resorption of molar pregnancy.

Dalmia S, Sivakumar K, Kathirvel R, Phillips K, Coady AM.

J Obstet Gynaecol. 2013 Apr;33(3):312-3. doi: 10.3109/01443615.2012.761187. No abstract available.

PMID:
23550870
15.

Polycystic ovary syndrome has no independent effect on vascular, inflammatory or thrombotic markers when matched for obesity.

Kahal H, Aburima A, Ungvari T, Rigby AS, Dawson AJ, Coady AM, Vince RV, Ajjan RA, Kilpatrick ES, Naseem KM, Atkin SL.

Clin Endocrinol (Oxf). 2013 Aug;79(2):252-8. doi: 10.1111/cen.12137. Epub 2013 May 11.

PMID:
23278130
16.

Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome.

Sathyapalan T, Shepherd J, Coady AM, Kilpatrick ES, Atkin SL.

J Clin Endocrinol Metab. 2012 Nov;97(11):3951-5. doi: 10.1210/jc.2012-2279. Epub 2012 Aug 9.

PMID:
22879630
17.

Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study.

Sathyapalan T, Smith KA, Coady AM, Kilpatrick ES, Atkin SL.

Ann Clin Biochem. 2012 Jan;49(Pt 1):80-5. doi: 10.1258/acb.2011.011071. Epub 2011 Oct 4.

PMID:
21972424
18.

Guidance on reporting ultrasound exposure conditions for bio-effects studies.

ter Haar G, Shaw A, Pye S, Ward B, Bottomley F, Nolan R, Coady AM.

Ultrasound Med Biol. 2011 Feb;37(2):177-83. doi: 10.1016/j.ultrasmedbio.2010.10.021. Review.

PMID:
21257086
19.

Insulin resistance variability in women with anovulatory and ovulatory polycystic ovary syndrome, and normal controls.

Cho LW, Kilpatrick ES, Keevil BG, Jayagopal V, Coady AM, Rigby AS, Atkin SL.

Horm Metab Res. 2011 Feb;43(2):141-5. doi: 10.1055/s-0030-1270450. Epub 2011 Jan 13.

PMID:
21234853
20.

Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome.

Sathyapalan T, Shepherd J, Arnett C, Coady AM, Kilpatrick ES, Atkin SL.

Clin Chem. 2010 Nov;56(11):1696-700. doi: 10.1373/clinchem.2010.144014. Epub 2010 Sep 3.

21.

Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS).

Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL.

Clin Endocrinol (Oxf). 2010 Apr;72(4):566-8. doi: 10.1111/j.1365-2265.2009.03678.x. Epub 2009 Aug 4. No abstract available.

PMID:
19681918
22.

Effect of rimonabant and metformin on glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 in obese women with polycystic ovary syndrome.

Sathyapalan T, Cho L, Kilpatrick ES, Le Roux CW, Coady AM, Atkin SL.

Clin Endocrinol (Oxf). 2010 Mar;72(3):423-5. doi: 10.1111/j.1365-2265.2009.03643.x. Epub 2009 May 29. No abstract available.

PMID:
19489873
23.

Metformin maintains the weight loss and metabolic benefits following rimonabant treatment in obese women with polycystic ovary syndrome (PCOS).

Sathyapalan T, Cho LW, Kilpatrick ES, Coady AM, Atkin SL.

Clin Endocrinol (Oxf). 2009 Jan;70(1):124-8. doi: 10.1111/j.1365-2265.2008.03345.x.

PMID:
19128368
24.

The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study.

Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL.

J Clin Endocrinol Metab. 2009 Jan;94(1):103-8. doi: 10.1210/jc.2008-1750. Epub 2008 Oct 21.

PMID:
18940877
25.

Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome.

Cho LW, Kilpatrick ES, Keevil BG, Coady AM, Atkin SL.

Clin Endocrinol (Oxf). 2009 Feb;70(2):233-7. doi: 10.1111/j.1365-2265.2008.03309.x. Epub 2008 Jun 10.

PMID:
18547343
26.

A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study.

Sathyapalan T, Cho LW, Kilpatrick ES, Coady AM, Atkin SL.

Clin Endocrinol (Oxf). 2008 Dec;69(6):931-5. doi: 10.1111/j.1365-2265.2008.03260.x. Epub 2008 Apr 10.

PMID:
18410553
27.

A newly recognized, likely autosomal recessive syndrome comprising agammaglobulinemia, microcephaly, craniosynostosis, severe dermatitis, and other features.

Crow YJ, Goodship JA, Wright C, Coady AM, Conley ME, Gennery AR.

Am J Med Genet A. 2006 Jun 1;140(11):1131-5.

PMID:
16691627
28.

Both msa genes in Renibacterium salmoninarum are needed for full virulence in bacterial kidney disease.

Coady AM, Murray AL, Elliott DG, Rhodes LD.

Appl Environ Microbiol. 2006 Apr;72(4):2672-8.

29.

Identification of a third msa gene in Renibacterium salmoninarum and the associated virulence phenotype.

Rhodes LD, Coady AM, Deinhard RK.

Appl Environ Microbiol. 2004 Nov;70(11):6488-94.

30.

Expression of duplicate msa genes in the salmonid pathogen Renibacterium salmoninarum.

Rhodes LD, Coady AM, Strom MS.

Appl Environ Microbiol. 2002 Nov;68(11):5480-7.

31.

Diagnosis and management of uterine arterio-venous malformations.

Nicholson AA, Turnbull LW, Coady AM, Guthrie K.

Clin Radiol. 1999 Apr;54(4):265-9. No abstract available.

PMID:
10210350
32.

Observer variability in the interpretation of contrast enhanced MRI of the breast.

Mussurakis S, Buckley DL, Coady AM, Turnbull LW, Horsman A.

Br J Radiol. 1996 Nov;69(827):1009-16.

PMID:
8958017
33.

Case report: MR imaging of fat necrosis of the breast associated with lipid cyst formation following conservative treatment for breast carcinoma.

Coady AM, Mussurakis S, Owen AW, Turnbull LW.

Clin Radiol. 1996 Nov;51(11):815-7. No abstract available.

PMID:
8937329
34.

Hyponatraemia secondary to cerebral salt wasting syndrome following routine pituitary surgery.

Atkin SL, Coady AM, White MC, Mathew B.

Eur J Endocrinol. 1996 Aug;135(2):245-7.

PMID:
8810741
35.

Multiple cerebral haematomata and peripheral nerve palsies associated with a case of juvenile diabetic ketoacidosis.

Atkin SL, Coady AM, Horton D, Sutaria N, Sellars L, Walton C.

Diabet Med. 1995 Mar;12(3):267-70.

PMID:
7758265
36.

Acute tubular necrosis induced by coronary thrombolytic therapy.

Kalra PA, Coady AM, Iqbal A, Evans A, Waldek S.

Postgrad Med J. 1991 Feb;67(784):212. No abstract available.

Supplemental Content

Loading ...
Support Center